FITC荧光Anti-C3c抗体(ab182868)
Key features and details
- FITC Goat polyclonal to C3c
- Suitable for: IHC-Fr, ELISA, ICC, ICC/IF
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG
概述
-
产品名称
FITC荧光Anti-C3c抗体
参阅全部 C3c 一抗 -
描述
FITC荧光山羊多克隆抗体to C3c -
宿主
Goat -
偶联物
FITC. Ex: 493nm, Em: 528nm -
经测试应用
适用于: IHC-Fr, ELISA, ICC, ICC/IFmore details -
种属反应性
与反应: Human -
免疫原
Full length native protein (purified) corresponding to Human C3c. C3c fragment is isolated and purified from pooled normal Human serum.
Database link: P01024 -
常规说明
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Lyophilized:It is reconstituted by adding 1.0 ml sterile distilled water, spun down to remove insoluble particles. -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. Store In the Dark. -
存储溶液
pH: 7.20
Constituent: 100% PBS -
Concentration information loading...
-
纯度
IgG fraction -
克隆
多克隆 -
同种型
IgG -
研究领域
相关产品
-
Isotype control
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab182868于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
IHC-Fr |
Use at an assay dependent concentration.
|
|
ELISA |
Use at an assay dependent concentration.
|
|
ICC |
Use at an assay dependent concentration.
|
|
ICC/IF |
Use at an assay dependent concentration.
|
说明 |
---|
IHC-Fr
Use at an assay dependent concentration. |
ELISA
Use at an assay dependent concentration. |
ICC
Use at an assay dependent concentration. |
ICC/IF
Use at an assay dependent concentration. |
靶标
-
功能
C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. -
组织特异性
Plasma. -
疾病相关
Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:613779]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. -
序列相似性
Contains 1 anaphylatoxin-like domain.
Contains 1 NTR domain. -
翻译后修饰
C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
Phosphorylation sites are present in the extracelllular medium. -
细胞定位
Secreted. - Information by UniProt
-
数据库链接
- Entrez Gene: 718 Human
- Omim: 120700 Human
- SwissProt: P01024 Human
- Unigene: 529053 Human
-
形式
Cleaved into the following 10 chains: 1) Complement C3 beta chain 2) Complement C3 alpha chain 3) C3a anaphylatoxin 4) Complement C3b alpha' chain 5) Complement C3c alpha' chain fragment 1 6) Complement C3dg fragment 7) Complement C3g fragment 8) Complement C3d fragment 9) Complement C3f fragment 10) Complement C3c alpha' chain fragment 2 -
别名
- acylation-stimulating protein cleavage product antibody
- AHUS5 antibody
- ARMD9 antibody
see all
实验方案
数据表及文件
-
Datasheet download
文献 (0)
ab182868 尚未被引用在任何文献中。